People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Rachel Norris, MD ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Beyond called off its $40 million investment deal with The Container Store. The parent company of Bed, Bath and Beyond in November cast doubt on the deal, expressing concerns the specialty retailer ...